Health Economics›Colorectal cancer›Advanced or metastatic disease KRAS inhibitor-naive

Advanced or metastatic disease KRAS inhibitor-naive

Colorectal cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Trifluridine and tipiracil monotherapy Variant #01	KRAS	R 1 067 070	28d	2.2 mo	10.3 mo	2	R 2 134 140 PFS proxy	4
Regorafenib monotherapy Variant #01	KRAS	R 132 655	28d	2.2 mo	10.3 mo	2	R 265 310 PFS proxy	4
Sotorasib and Panitumumab Variant #01 Partial	KRAS	R 25 254	14d	4.8 mo	11.9 mo	2	R 50 508 PFS proxy	4

3 of 3 regimens shown